Free Trial
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel
LON:SCLP

Scancell Interim Earnings Report

Scancell logo
GBX 22.86 -0.89 (-3.75%)
As of 12:36 PM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 1.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Interim
Date
1/30/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Scancell Holdings Plc: Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68321153-scancell-holdings-plc-scancell-receives-fda-fast-track-designation-for-iscib1-in-advanced-melanoma-and-provides-data-update-from-its-scope-phase-2-s-399.htm
Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats up
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/scancells-melanoma-data-keeps-widening-073900849.html
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
June 3 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
April 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/scancell-receives-fda-fast-track-060000103.html
Scancell CFO to step down as cancer immunotherapy developer names interim replacement
April 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/scancell-cfo-step-down-cancer-062000055.html
Scancell Holdings plc (LON:SCLP) has caught the attention of institutional investors who hold a sizeable 46% stake
January 31, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/scancell-holdings-plc-lon-sclp-075522999.html
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.

View Scancell Profile
Earnings Tools